Vaccination as a treatment for breast or ovarian cancer

References

• Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. 46(6), 3118–3124 (1986).
   PubMed Web of Science ®Google Scholar
• Reddish MA, Jackson L, Koganty RR et al Specificities of antisialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes. Glycocopj. J. 14(5), 549–560 (1997).
   Google Scholar
• Girling A, Bartkova J, Burchell J et al A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int. J. Cancer. 43(6), 1072–1076 (1989).
   Google Scholar
• Kinney AY, Sahin A, Vernon SW et al. The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer80(12), 2240–2249 (1997).
   Google Scholar
• Miles DW, Happerfield LC, Smith P et al. Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer. Br. .1. Cancer 70(6) 1272–1275 (1994).
   Google Scholar
• Kobayashi H, Terao T, Kawashima Y et al. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. I Clin. OncoL 10(1), 95–101 (1992).
   Google Scholar
• von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, Verstraeten AA. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUCI). Tumor Biol. 19(3), 186–195 (1998).
   PubMedGoogle Scholar
• Jerome KR, Barnd DL, Bendt KM et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51(11), 2908–2916 (1991).
   Google Scholar
• Fung PY, Madej M, Koganty RR, Longenecker BM. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor- associated glycoconjugate. Cancer Res. 50(14), 4308–4314 (1990).
   PubMed Web of Science ®Google Scholar
• Fung PY, Longenecker BM. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res. 51(4), 1170–1176 (1991). itEhrke MJ, Mihich E, Berd D, Mastrangelo MJ. Effects of anticancer drugs on the immune system in humans. Semin. OncoL 16(3), 230–253 (1989).
   Google Scholar
• Ehrke MJ, Mihich E, Berd D, Mastrangelo MJ. Effects of anticancer drugs on the immune system in humans. Semin. Oncol.
   Google Scholar
• Longenecker BM, Reddish M, Koganty R, MacLean GD. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Ann. NY Acad. Sci. 690,276–291 (1993).
   PubMed Web of Science ®Google Scholar
• •Immune responses elicited by Theratope.
   Google Scholar
• MacLean GD, Reddish M, Koganty RR, Wong T. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer ImmunoL Immunother. 36(4), 215–222 (1993).
   PubMed Web of Science ®Google Scholar
• •Nontransplant clinical trials with Theratope.
   Google Scholar
• Longenecker BM, Raddish M, Miles D et aL Synthetic tumor-associated sialyl-Tn antigen as an immunotherapeutic cancer vaccine. Vaccine Res. 2,151–162 (1993).
   Google Scholar
• Miles DW, Towlson KE, Graham R etal. A randomized Phase II study of sialyl-Tn and Detox-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 74(8), 1292–1296 (1996).
   Google Scholar
• ••Nontransplant clinical trial withTheratope demonstrating the benefits of intravenous Cytoxan.
   Google Scholar
• MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM. Enhancing the effect of Theratope STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. Immunother. Emphasis Tumor ImmunoL 19(4), 309–316 (1996).
   Google Scholar
• ••Nontransplant clinical trials withTheratope.
   Google Scholar
• Miles D, Papazisis K. Rationale for the clinical development of STn-KLH (Theratope®) and anti-MUC-1 vaccines in breast cancer. Clin. Breast Cancer. 3\(Suppl. 4), S134—S138 (2003).
   PubMedGoogle Scholar
• MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immunother. Emphasis Tumor ImmunoL 19(1), 59–68 (1996).
   PubMed Web of Science ®Google Scholar
• Reddish MA, MacLean GD, Poppema S, Berg A, Longenecker BM. Pre- immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer ImmunoL Immunother. 42(5), 303–309 (1996).
   PubMed Web of Science ®Google Scholar
• Yacyshyn MB, Poppema S, Berg A et al CD69+ and HLA-DR activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy. Int. J. Cancer 61(4) 470–474 (1995).
   Google Scholar
• Holmberg LA, Oparin DV, Gooley T et al. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and Theratope STn-KLH cancer vaccine. Bone Marrow Transplant. 25 (12), 1233–1241 (2000). Theratope after autologous transplant.
   Google Scholar
• Holmberg LA, Oparin DV, Gooley T, Sandmaier BM. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope®). Clin. Breast Cancer. 3\(Suppl. 4), S144—S151 (2003).
   PubMedGoogle Scholar
• •• Clinical outcome after autologous transplant and Theratope.
   Google Scholar
• Sandmaier BM, Oparin DV, Holmberg LA et al. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue and immunization with Theratope STn-KLH cancer vaccine. J Immunother. 22(1), 54–66 (1999).
   Google Scholar
• •Immunological responses to Theratope after autologous transplant.
   Google Scholar
• Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 92(5), 1471–1490 (1998).
   PubMed Web of Science ®Google Scholar
• Miles D, Ibrahim N, Roche H et al. An international, randomized Phase III clinical trial of STn- KLH (Theratope®) therapeutic cancer vaccine in metastatic breast cancer patients. Proc. 27th Ann. San Antonio Breast Cancer Symp. San Antonio, TX, USA, 36 (2003).
   Google Scholar
• ••Phase III randomized Theratope clinicaltrial in metastatic breast cancer patients.
   Google Scholar
• Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH et al. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC-1 peptide vaccination of breast cancer patients. Int. J Cancer 93(1), 97–106 (2001).
   Google Scholar
• •Antibody to MUC-1 induces antibody-dependent cell-mediated cytotoxicity killing.
   Google Scholar
• Doehn C, Jocham D. Technology evaluation: TG-1031, transgene SA. Cum: Opin. MoL Ther. 2(1), 106–111 (2000).
   PubMedGoogle Scholar
• Scholl SM, Balloul JM, Le Goc G et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother. 23(5), 570–580 (2000).
   Google Scholar
• Miles D, Uziely B, Va SB et al. A Phase II study of a gene-modified vaccinia virus expressing MUC-1 and interleukin-2 (VV-MUC1-1L2, TG1031), in patients with metastatic breast cancer (Meeting abstract). Proc. 35th Ann. ASCO Meeting. Atlanta, GA, USA, 1684 (1999).
   Google Scholar
• •No correlation of clinical outcome with immune responses in MUC-1/Vaccinia/IL2 vaccine.
   Google Scholar
• Musselli C, Ragupathi G, Gilewski T etal. Re-evaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int. J. Cancer 97(5), 660–667 (2002).
   Google Scholar
• •Inconsistent immune responses to MUC-1.
   Google Scholar
• Graham RA, Burchell JM, Beverley P, Taylor-Papadimitriou J. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumor cells. Int. J. Cancer 65(5), 664–670 (1996).
   PubMedGoogle Scholar
• Apostolopoulos V, Pietersz GA, McKenzie IF. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 14(9), 930–938 (1996).
   PubMed Web of Science ®Google Scholar
• Lees CJ, Apostolopoulos V, Acres B etal. Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice. Vaccine 19(2–3), 158–162 (2000).
   Google Scholar
• Gong J, Apostolopoulos V, Chen D et al. Selection and characterization of MUC1-specific CD8+ T-cells from MUC1 transgenic mice immunized with dendritic—carcinoma fusion cells. Immunology101(3), 316–324 (2000).
   Google Scholar
• Mukherjee P, Madsen CS, Ginardi AR etal. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. Immunother 26(1), 47–62 (2003).
   Google Scholar
• •MUC-1 murine model.
   Google Scholar
• Reilly RT, Machiels JP, Emens LA et al. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. 61(3), 880–883 (2001).
   Google Scholar
• Chen L, Ashe S, Brady WA et al. Costimulation of antitumor immunity by the B7 counter-receptor for the T-lymphocyte molecules CD28 and CTLA-4. Ce1171(7), 1093–1102 (1992).
   Google Scholar
• •Humoral and cellular responses to Her-2/neu.
   Google Scholar
• Baxevanis CN, Gritzapis AD, Tsitsilonis OE, Katsoulas HL, Papamichail M. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes. Int. J. Cancer98(6), 864–872 (2002).
   Google Scholar
• •Natural killer cells recognize Her-2/neu.
   Google Scholar
• Murray JL, Gillogly ME, Przepiorka D et al. Toxicity, immunogenicity and induction of E75-specific tumor-ly tic CTLs by HER-2 peptide E75 (369–377) combined with granulocyte—macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin. Cancer Res. 8(11), 3407–3418 (2002).
   Google Scholar
• •• Her-2/neu vaccine trial.
   Google Scholar
• Disis ML, Smith RV, Murphy AE, Chen W, Cheever MA. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res. 54(4), 1071–1076 (1994).
   Google Scholar
• •Immune responses to Her-2/neu vaccine.
   Google Scholar
• Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin. Invest. 107(4), 477–484 (2001).
   PubMed Web of Science ®Google Scholar
• •Immune responses to Her-2/neu vaccine.
   Google Scholar
• Disis ML, Schiffman K, Gooley TA et al. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin. Cancer Res. 6(4), 1347–1350 (2000).
   Google Scholar
• Disis ML, Gooley TA, Rinn K et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. One& 20(11), 2624–2632 (2002).
   Google Scholar
• ••Maximizing immune T-cell responses toHer-2/neu vaccine.
   Google Scholar
• Chen Y, Emtage P, Zhu Q et aL Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther. 8(4), 316–323 (2001).
   Google Scholar
• Efferson CL, Schickli J, Ko BK et al. Activation of tumor antigen-specific cytotoxic T-lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene. Virol 77(13), 7411–7424 (2003).
   Google Scholar
• Yip YL, Smith G, Koch J, Dubel S, Ward RL. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J Immunol. 166 (8), 5271–5278 (2001).
   PubMedGoogle Scholar
• Wagner U, Kohler S, Reinartz S et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin. Cancer Res. 7(5), 1154–1162 (2001).
   Google Scholar
• ••Immune response with anti-idiotype toantibody to CA125 associated with outcome.
   Google Scholar
• Reinartz S, Boerner H, Koehler S et al Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines-a preliminary report. Hybridoma 18(1), 41–45 (1999).
   Google Scholar
• Battacharya-Chatterjee M, Mrozek E, Mukerjee S et al. Anti-idiotype antibodies as potential therapeutic agents for human breast cancer. In: Proceed. 5th Int. Workshop on Breast Cancer Therapy and Immunol Ceriani P (Ed.), Plenum, NY, USA. 387–401 (1994).
   Google Scholar
• Reece DE, Foon KA, Battacharya-Chatterjee M et aL Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. Clin. Breast Cancer. 2(1), 52–58 (2001).
   Google Scholar
• •• Clinical outcome and immune response with 11D10 post autologous transplant.
   Google Scholar
• Plunkett TA, Miles DW. New biological therapies for breast cancer. Int. J Clin. Pract. 56(4), 261–266 (2002).
   PubMed Web of Science ®Google Scholar
• Disis ML, Rinn K, Knutson KL et al. F1t3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 99(8), 2845–2850 (2002).
   Google Scholar
• Brossart P, Wirths S, Brugger W, Kanz L. Dendritic cells in cancer vaccines. Exp. Hematol 29(11), 1247–1255 (2001).
   PubMedGoogle Scholar
• Engleman EG, Fong L. Induction of immunity to tumor associated antigens following dendritic cell vaccination of cancer patients. Clin. Imm. 106,10–15 (2003).
   PubMedGoogle Scholar
• Dillman RO, Nayak SK, Brown JV, Mahdavi K, Beutel LD. The feasibility of using short-term cultures of ovarian cancer cells for use as autologous tumor cell vaccines as adjuvant treatment of advanced ovarian cancer. Cancer Biother. Radiopharm. 14(6), 443–449 (1999).
   PubMedGoogle Scholar
• Berd D. Autologous, hapten-modified vaccine as a treatment for human cancers. Vaccine 19(17–19), 2565–2570 (2001).
   Google Scholar
• Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T-cells. Cancer Immunol. Immunother 50(1), 3–15 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Progress in human tumor immunology and immunotherapy. Nature 411(6835), 380–384 (2001).
   PubMed Web of Science ®Google Scholar
• Schaaf DD, Smith RV 2nd, Disis ML et al. Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF. Adv. Exp. Med. Biol. 451,511–518 (1998).
   PubMed Web of Science ®Google Scholar
• Dols A, Smith RV 2nd, Meijer SL et al. Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum. Gene Ther 14(11), 1117–1123 (2003).
   Google Scholar
• •Allogeneic tumor cancer vaccines.
   Google Scholar
• Dols A, Meijer SL, Hu HM etal. Identification of tumor-specific antibodiesin patients with breast cancer vaccinatedwith gene-modified allogeneic tumor cells.Immunother 26(2), 163–170 (2003).
   Google Scholar
• •Allogeneic tumor cancer vaccines.
   Google Scholar
• Nishikawa H, Tanida K, Ikeda H et al. Role of SEREX-defined immunogenic wild type cellular molecules in the development of tumor-specific immunity. Proc. Nat/Acad. Sci. 98(25), 14571–14576 (2001).
   Google Scholar
• Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of Cellular antigens and the generation of myeloma-specific killer T-cells by dendritic cells. J Exp. Med. 195(1), 125–33 (2002).
   PubMed Web of Science ®Google Scholar
• Curcio C, Di Carlo E, Clynes R etal. Nonredundant roles of antibody, cytokines and perforin in the eradication of established Her-2/neu carcinomas. J Clin. Invest. 111(8),1161-1170 (2003).
   Google Scholar
• •Regressing tumors have both inflammatory changes and polyclonal T-and B-cells.
   Google Scholar